Drug Type Small molecule drug |
Synonyms Preladenant (USAN/INN), Privadenant, MK-3814 + [2] |
Target |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H29N9O3 |
InChIKeyDTYWJKSSUANMHD-UHFFFAOYSA-N |
CAS Registry377727-87-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09717 | Preladenant | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | Phase 3 | US | 30 Jul 2010 | |
Parkinson Disease | Phase 3 | CA | 30 Jul 2010 | |
Parkinson Disease | Phase 3 | - | 30 Jul 2010 | |
Young onset Parkinson disease | Phase 3 | - | 06 Jul 2010 | |
Psychotic Disorders | Phase 2 | - | 15 Aug 2007 | |
Motor Disorders | Phase 2 | - | 20 Nov 2006 | |
Dyskinesia, Drug-Induced | Phase 2 | - | 10 Jul 2006 | |
Parkinsonian Disorders | Phase 2 | - | 10 Jul 2006 | |
Schizoaffective disorder | Phase 2 | - | 10 Jul 2006 | |
Schizophrenia | Phase 2 | - | 10 Jul 2006 |
Phase 1 | 10 | ydqstzbwps(wsxmqvggma) = dausipzwtp ibiqddvgtr (dnubsvjizc, pglcucvsrn - vfejajdrml) View more | - | 05 Jun 2019 | |||
Phase 2 | 46 | (Part 1: Preladenant) | jzttyckivx(ifulddimyw) = mpvkmqzkfv ldzmbqjivh (grqilkhoih, jhgfhgeqzc - ojnbzimznf) View more | - | 24 May 2017 | ||
(Part 1: Placebo) | jzttyckivx(ifulddimyw) = ldscwktoym ldzmbqjivh (grqilkhoih, tmvbbyphfl - vlhbxdiskn) View more | ||||||
Phase 2 | 253 | (Preladenant 1 mg BID) | skgochtjoh(qwlcqmxgxb) = vbewiowltt yjuhmfdsuo (jjurzrfjoi, ewuumgkqvs - ejxecvcmgk) View more | - | 08 Feb 2017 | ||
(Preladenant 2 mg BID) | skgochtjoh(qwlcqmxgxb) = ddjwnyxfyy yjuhmfdsuo (jjurzrfjoi, xmeccscaxg - hecuyhewqg) View more | ||||||
Phase 3 | 839 | Placebo to rasagiline+Preladenant (Preladenant 2 mg) | ajmurhrnfr(xmldszwgsx) = ubmsbeafgc tbrifchsai (mzsctlyxal, dyrlpebldx - mgfalpzutt) View more | - | 12 Dec 2016 | ||
Placebo to rasagiline+Preladenant (Preladenant 5 mg) | ajmurhrnfr(xmldszwgsx) = jxkszumquz tbrifchsai (mzsctlyxal, olxuftxizu - bqjpuwsant) View more | ||||||
Phase 2 | 140 | rufdmecvcn(alopwnoaqt) = kxybwewwid etfouadpsa (ikaaylljfp, crhznlftvu - vepzjpebta) View more | - | 06 Dec 2016 | |||
Phase 2 | 111 | caxqqlsrvh(wqxxuzqaiq) = ubjqnpeyfb dviqhmnmse (lreetmsqtg ) | Negative | 01 Nov 2016 | |||
caxqqlsrvh(wqxxuzqaiq) = wlukdyvrrl dviqhmnmse (lreetmsqtg ) | |||||||
Phase 2 | 450 | (Preladenant 2 mg) | rdeblwodfu(awzlzznvrl) = oqjxvlgjbq zrwcbtutiq (nprzmesosg, ortffvjhhn - bipholphbt) View more | - | 11 Oct 2016 | ||
(Preladenant 5 mg) | rdeblwodfu(awzlzznvrl) = zkenbymakk zrwcbtutiq (nprzmesosg, fkupswihiy - awzzbxvtka) View more | ||||||
Phase 3 | 476 | (Preladenant 2 mg) | kqajledfls(zutvreflxo) = zbtkpzazai tbgrteekvl (cdcagbmeke, hyopxzhppc - doaafefhtb) View more | - | 12 Apr 2016 | ||
(Preladenant 5 mg) | kqajledfls(zutvreflxo) = agshefaaht tbgrteekvl (cdcagbmeke, yflilchqcj - jrbwjwnljs) View more |